Bodyport combines several fluid and cardiac measurements in a familiar home scale, rather than relying on weight alone. The Cardiac Scale sends readings directly to clinicians by cellular connection, while its Care Platform displays the Congestion Index beside the underlying trends.
In the prospective observational SCALE-HF 1 study of 329 participants, the Congestion Index preceded 48 of 69 adjudicated worsening heart failure events, compared with 24 of 69 for weight-based rules. Bodyport reported 2.58 alerts per patient-year for the index and 4.18 for weight rules; these study results support a measured difference in monitoring performance, without establishing a universal clinical outcome.
Bodyport is moving its home-monitoring system into clinical use for heart failure and other fluid-management conditions. The company said in September 2024 that organizations were implementing the FDA-cleared Cardiac Scale and Clinical Dashboard in commercial care settings, following its observational SCALE-HF 1 results.
The study measured event-warning performance and alert volume, while Bodyport's software provides trends, rules, and workflow integrations for care teams. The reported findings describe a clinical use case and deployment activity; they do not quantify adoption, revenue, or a share of the wider remote-monitoring market.
Bodyport's Cardiac Scale measures weight, peripheral impedance, pulse rate, and balance during a brief daily step at home. It sends those measurements to a clinical team over cellular connectivity, so patients do not need to pair the device with their own home network.
Bodyport's separate clinician-facing Care Platform displays measurement trends and the Congestion Index, a composite derived from scale parameters. The software also offers configurable monitoring rules, patient prioritization, documentation, an API, and electronic health record integrations for remote care workflows.